Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00093834 | Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer | completed | Phase 1 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01837602 | cMet CAR RNA T Cells Targeting Breast Cancer | completed | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05860582 | A Study of [14C]GB491 in Male Healthy Subjects | completed | Phase 1 | 6 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT02531425 | Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC(TNBC) | completed | Phase 1 | 10 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03310541 | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04097756 | A Phase I Study of LX-039 Tablets | completed | Phase 1 | 44 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00337649 | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01922921 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | completed | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05812326 | PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02027376 | Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients(EDALINE) | completed | Phase 1 | 12 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT01306942 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | completed | Phase 1 / Phase 2 | 37 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT04382352 | B002 in Patients With HER2-positive Breast Cancer(B002-101) | completed | Phase 1 | 23 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Prelude TherapeuticsINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05298696 | Efficacy of Cilostazol in Prevention of Peripheral Neuropathy | completed | Phase 1 / Phase 2 | 71 | Mansoura UniversityOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT05765357 | Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers | completed | Phase 1 | 89 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03916744 | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 | 75 | Genentech, Inc.INDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT01969643 | A Safety Study of SGN-LIV1A in Breast Cancer Patients | completed | Phase 1 | 290 | Seagen Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT00129896 | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | completed | Phase 1 / Phase 2 | 73 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02742935 | A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects | completed | Phase 1 | 99 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT04514159 | A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | completed | Phase 1 | 14 | Zeno Alpha Inc.INDUSTRY | 2 | Feb 1, 2023 | clinicaltrials |
| NCT02236000 | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 49 | NSABP Foundation IncNETWORK | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05471648 | A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers | completed | Phase 1 | 135 | EirGenix, Inc.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02652923 | Contrast Ultrasound Detection of Sentinel Lymph Nodes | completed | Phase 1 / Phase 2 | 98 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03430479 | Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT03477019 | Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | St. Olavs HospitalOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03323658 | Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05052437 | PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer | completed | Phase 1 | 16 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02438358 | Feasibility Study of Intraoperative Imaging in Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Lumicell, Inc.INDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05252546 | Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects | completed | Phase 1 | 36 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04080024 | A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer(SPAGOPIX-01) | completed | Phase 1 | 14 | Spago Nanomedical ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04132817 | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03344536 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02479230 | Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients | completed | Phase 1 | 18 | Joseph Baar, MD, PhDOTHER | 1 | Nov 22, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jul 3, 2023source: clinicaltrials